Philippe was previously Sr VP Neurosciences R&D at Ipsen, based in Cambridge (USA). He joins us with a large experience in R&D and business development, in particular in the field of neurology. Philippe is a pharmacist and his qualifications include an MSc in fundamental and applied toxicology, an MSc in anatomopathology, and a diploma of the American Board of Toxicology.
Philippe brings a wealth of expertise as AlgoTherapeutix prepares to raise a Series A to launch ATX01 into clinical development for Chemotherapy-Induced Peripheral Neuropathy.
AlgoTherapeutix is a French biotech start-up, hosted by the Paris Biotech Santé incubator developing ATX01, a treatment for Chemotherapy-Induced Peripheral Neuropathy.
- AlgoTherapeutix SAS
- 49 rue des Nouvelles – 92150 Suresnes
- Contact : email@example.com